Clinica chimica acta; international journal of clinical chemistry · 2026
Comparative diagnostic utility of cerebrospinal fluid biomarkers in multiple sclerosis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rashad Basant, Sayed Sohair K, Rageh Tarek A, Badawy Eman R, Kamal Dalia T
Аннотация
BACKGROUND: Multiple sclerosis (MS) diagnosis depends on clinical and magnetic resonance imaging (MRI) data; the need for confirmatory cerebrospinal fluid (CSF) biomarkers for differential diagnosis is a crucial step.
OBJECTIVE: We aim to investigate and compare the diagnostic value of CSF markers (e.g., chitinase 3-like 1 (CHI3L1), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP)) compared to the established supportive diagnostic oligoclonal bands test (OCBs) in MS.
METHODS: We collected 62 CSF samples from suspected MS patients with T2-Hyperintense lesions and investigated OCBs and enzyme-linked immunosorbent assay (ELISA) for NfL, CHI3L1, and GFAP.
RESULTS: The CSF levels of NfL (p < 0.001) and CHI3L1 (p < 0.001) were significantly elevated in the MS group compared to the non-MS group, in contrast to GFAP (p = 0.17). Diagnostic criteria for MS diagnosis was excellent for OCBs (Area under curve (AUC) = 0.978, p < 0.001; 95% Confidence Interval (CI): 0.929-1.000), good for CHI3L1 (AUC = 0.838, p < 0.001; 95% CI: 0.738-0.939), acceptable for NfL (AUC = 0.729, p = 0.003; 95% CI: 0.602-0.855) and poor for GFAP (AUC = 0.604, p = 0.173; 95% CI: 0.477-0.762).
CONCLUSION: Among the studied biomarkers, CHI3L1 showed potential as an adjunctive biomarker for discriminating MS from non-MS patients. Its diagnostic accuracy was higher than that of NfL in our cohort, but GFAP has limited diagnostic accuracy, which could restrict its use in MS diagnosis.
OBJECTIVE: We aim to investigate and compare the diagnostic value of CSF markers (e.g., chitinase 3-like 1 (CHI3L1), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP)) compared to the established supportive diagnostic oligoclonal bands test (OCBs) in MS.
METHODS: We collected 62 CSF samples from suspected MS patients with T2-Hyperintense lesions and investigated OCBs and enzyme-linked immunosorbent assay (ELISA) for NfL, CHI3L1, and GFAP.
RESULTS: The CSF levels of NfL (p < 0.001) and CHI3L1 (p < 0.001) were significantly elevated in the MS group compared to the non-MS group, in contrast to GFAP (p = 0.17). Diagnostic criteria for MS diagnosis was excellent for OCBs (Area under curve (AUC) = 0.978, p < 0.001; 95% Confidence Interval (CI): 0.929-1.000), good for CHI3L1 (AUC = 0.838, p < 0.001; 95% CI: 0.738-0.939), acceptable for NfL (AUC = 0.729, p = 0.003; 95% CI: 0.602-0.855) and poor for GFAP (AUC = 0.604, p = 0.173; 95% CI: 0.477-0.762).
CONCLUSION: Among the studied biomarkers, CHI3L1 showed potential as an adjunctive biomarker for discriminating MS from non-MS patients. Its diagnostic accuracy was higher than that of NfL in our cohort, but GFAP has limited diagnostic accuracy, which could restrict its use in MS diagnosis.